☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Fast track designation
Calliditas Receives the US FDA's Fast Track Designation for Setanaxib to Treat Primary Biliary Cholangitis
August 9, 2021
Lysogene Receives the US FDA's Fast Track Designation for LYS-GM101 Gene Therapy to Treat GM1 Gangliosidosis
July 9, 2021
Fulcrum Therapeutics' Losmapimod Receives the US FDA's Fast Track Designation to Treat Facioscapulohumeral Muscular Dystrophy
May 13, 2021
LEXEO Therapeutics Receives the US FDA's Fast Track Designation for LX1001 to Treat APOE4 Associated Alzheimer Disease
April 21, 2021
Vertex's VX-880 Receives the US FDA's Fast Track Designation for T1D
March 11, 2021
Targovax Receives US FDA's Fast Track Designation for ONCOS-102 for Malignant Pleural Mesothelioma
February 16, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.